Results from the phase 3 KEYNOTE-826 trial show a significant survival benefit with pembrolizumab plus chemotherapy with or without bevacizumab in most patient subgroups with persistent, recurrent, or metastatic cervical cancer.
Patients with advanced human papillomavirus 16–positive cervical cancer appear to benefit from treatment with VB10.16 and atezolizumab.
Patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 can receive treatment with pembrolizumab plus chemotherapy with or without bevacizumab following approval by the European Commission.
At SGO 2022, Jyoti S. Mayadev, MD presented results of the NRG-GY017 trial of atezolizumab as either an immune primer or with chemoradiation for certain patients with locally advanced cervical cancer.
At SGO 2022, CancerNetwork® spoke with Jyoti Mayadev, MD, about a clinical trial involving immune priming with the PD-L1 inhibitor atezolizumab for patients with locally advanced cervical cancer.
Patients with locally advanced cervical cancer did not see further benefit from the addition of concurrent durvalumab to chemoradiotherapy.
Results of the phase 1 NRG-GY017 trial show promise of atezolizumab as an immune primer in locally advanced cervical cancer.
Updated results from the KEYNOTE-826 study show a favorable risk-benefit ratio for pembrolizumab plus chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer.
An anti-TIGIT/anti–PD-1 combination approach with ociperlimab plus tislelizumab will be examined in a phase 2 study of patients with previously treated recurrent or metastatic cervical cancer.
Patients with recurrent cervical cancer appeared to achieve a promising survival benefit following treatment with cemiplimab.